Stockscreener 앱 받기
0.6603
4.44%
-0.0307
Biodexa Pharmaceuticals Plc Adr 주식(BDRX)의 최신 뉴스
Biodexa partners with Tanner Pharma for FAP drug early access By Investing.com - Investing.com Australia
Biodexa Launches Global Early Access Program for eRapa for - GlobeNewswire
Biodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strategic Partnership with Tanner Pharma Group - markets.businessinsider.com
Biodexa partners with Tanner Pharma for FAP drug early access - Investing.com
Biodexa opens first non-trial access to eRapa for FAP patients - Stock Titan
Biodexa (NASDAQ: BDRX) director reports detailed stock option holdings - Stock Titan
Biodexa Pharmaceuticals announces ADR ratio change - MSN
Biodexa Pharmaceuticals changes ADR ratio to meet Nasdaq rules By Investing.com - Investing.com Australia
Biodexa Pharmaceuticals Announces Reverse ADR Split to Support Nasdaq Compliance - TipRanks
Biodexa Pharmaceuticals (BDRX) Announces ADR Ratio Change - GuruFocus
Biodexa Pharmaceuticals changes ADR ratio to meet Nasdaq rules - Investing.com
Biodexa Pharmaceuticals PLC Announces ADR Ratio Change to Comply with Nasdaq Minimum Bid Price Requirement - Quiver Quantitative
Reverse ADR split at Biodexa (Nasdaq: BDRX) targets Nasdaq $1 bid rule - Stock Titan
ADR Ratio Change - Bitget
Biodexa Pharmaceuticals (NASDAQ: BDRX) director lists stock option position - Stock Titan
Biodexa (NASDAQ: BDRX) CEO lists detailed stock option holdings - Stock Titan
Biodexa Pharmaceuticals (NASDAQ: BDRX) director details ADS option stake - Stock Titan
Biodexa (BDRX) CFO details multi-year stock option grants - Stock Titan
Biodexa Pharmaceuticals (BDRX) director Simon Turton reports initial equity holdings - Stock Titan
BDRX SEC FilingsBiodexa Pharmaceuticals plc 10-K, 10-Q, 8-K Forms - Stock Titan
Biodexa Announces Support for Life’s a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients - ChartMill
New U.S. group for those facing near-100% colon cancer risk, backed by Biodexa - Stock Titan
BDRXBiodexa Pharmaceuticals plc Latest Stock News & Market Updates - Stock Titan
Biodexa Pharmaceuticals (NASDAQ:BDRX) Upgraded at Wall Street Zen - Defense World
Biodexa Licenses Phase 1 Ready Drug Candidate from Otsuka for Rare Stomach Cancer - Finviz
New molecular glue drug aims to tackle deadly stomach tumors - Stock Titan
Biodexa Announces Exclusive License of Otsuka’s OPB-171775, a potent Phase 1 ready Molecular Glue for GIST - markets.businessinsider.com
Biodexa licenses Otsuka’s molecular glue compound for GIST treatment By Investing.com - Investing.com India
Biodexa licenses Otsuka’s molecular glue compound for GIST treatment - Investing.com
Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Short Interest Update - Defense World
Biodexa Pharmaceuticals promotes Fiona Sharp to CFO, secretary - Yahoo Finance
Biodexa pharmaceuticals appoints Fiona Sharp as CFO and board member By Investing.com - Investing.com India
Biodexa pharmaceuticals appoints Fiona Sharp as CFO and board member - Investing.com
Biodexa Pharmaceuticals Faces Market Challenges as Stocks Decline - StocksToTrade
Short Interest in Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Expands By 298.4% - Defense World
Biodexa Pharmaceuticals prices 157,000 units at $3.28 in public offering - TipRanks
Biodexa Pharmaceuticals stock falls after $10 million public offering By Investing.com - Investing.com South Africa
Biodexa Pharmaceuticals stock falls after $10 million public offering - Investing.com
Biodexa prices $10 million public offering of units and warrants - Investing.com
Biodexa prices $10 million public offering to fund development programs - Investing.com
Biodexa prices $10 million public offering to fund development programs By Investing.com - Investing.com UK
Why B. Riley Financial Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket - Benzinga
Biodexa Pharmaceuticals (NASDAQ:BDRX) Shares Down 53.8% – Time to Sell? - Defense World
Biodexa Pharmaceuticals (NASDAQ: BDRX) Stock on December 10, 2025: Violent Rally, Phase 3 FAP Progress and What 2026 Might Hold - ts2.tech
Wall Street analysts’ outlook for Biodexa Pharmaceuticals Plc ADR (BDRX) - setenews.com
Biodexa Pharmaceuticals (NASDAQ: BDRX) outlines major unit deal with complex zero-cash warrants - Stock Titan
Biodexa enrolls first European patients in phase 3 FAP trial By Investing.com - Investing.com South Africa
Biodexa enrolls first European patients in phase 3 FAP trial - Investing.com
EBIT per share of Biodexa Pharmaceuticals plc Sponsored ADR – FWB:5MP - TradingView
[424B3] Biodexa Pharmaceuticals Plc Prospectus Filed Pursuant to Rule 424(b)(3) - Stock Titan
Biodexa activates first European site for phase 3 FAP trial By Investing.com - Investing.com India
Biodexa activates first European site for phase 3 FAP trial - Investing.com
Biodexa Pharmaceuticals plc (BDRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Biodexa Pharmaceuticals (NASDAQ:BDRX) Stock Price Down 0.4% – What’s Next? - Defense World
[POS AM] Biodexa Pharmaceuticals Plc SEC Filing - Stock Titan
Total debt per share of Biodexa Pharmaceuticals plc Sponsored ADR – BER:5MP - TradingView
What Makes Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) a New Buy Stock - MSN
Holdings of Biodexa Pharmaceuticals Plc ADR (BDRX) are aligned with the stars - setenews.com
0.04%
0.06%
자본화:
|
볼륨(24시간):